ITGB1BP1, a Novel Transcriptional Target of CD44-Downstream Signaling Promoting Cancer Cell Invasion

Abstract

Breast cancer (BC) is the most common malignancy worldwide and has a poor prognosis, because it begins in the breast and disseminates to lymph nodes and distant organs. While invading, BC cells acquire aggressive characteristics from the tumor microenvironment through several mechanisms. Thus, understanding the mechanisms underlying the process of BC cell invasion can pave the way towards the development of targeted therapeutics focused on metastasis. We have previously reported that the activation of CD44 receptor with its major ligand hyaluronan (HA) promotes BC metastasis to the liver in vivo. Next, a gene expression profiling microarray analysis was conducted to identify and validate CD44-downstream transcriptional targets mediating its pro-metastatic function from RNA samples collected from Tet CD44-induced versus control MCF7-B5 cells. We have already validated a number of novel CD44-target genes and published their underlying signaling pathways in promoting BC cell invasion. From the same microarray analysis, Integrin subunit beta 1 binding protein 1 ( ITGB1BP1 ) was also identified as a potential CD44-target gene that was upregulated (2-fold) upon HA activation of CD44. This report will review the lines of evidence collected from the literature to support our hypothesis, and further discuss the possible mechanisms linking HA activation of CD44 to its novel potential transcriptional target ITGB1BP1 .

Exome sequencing identifies ADGRG4 G‐protein‐coupled receptors gene as a novel cancer biomarker in ovarian cancer patients from North India

“…ITGB1BP1 is involved in various cellular processes, including cell growth, division, adherence, migration, mineralization, bone formation, and angiogenesis. [ 39 ]…”

CD44 and its implication in neoplastic diseases

“…Recent advances in understanding the complex interactions of CD44 with ligands have led to the development of CD44 not only as an important cancer stem cells (CSCs) marker but also as a potential cancer therapeutic target. 3 , 19 , 20 In neoplastic diseases therapeutic areas, it is very crucial to clarify the mechanism of CD44 in the signaling pathways, thereby delaying, treating, and preventing the development of tumors through targeting CD44. However, there are relatively few clinical studies about CD44‐targeted therapies in cancer treatment.…”